As every year, ASH 2021 brought us updates on current practice, new insights and promising future treatments. I have tried to select the most relevant data from the educational sessions and oral and poster abstracts that can influence our current and near-future practice in chronic myeloid leukaemia (CML) and myeloproliferative neoplasm (MPN).

(BELG J HEMATOL 2022;13(1):17–24)